What is William Blair's Estimate for ABT FY2025 Earnings?

Abbott Laboratories (NYSE:ABT - Free Report) - Stock analysts at William Blair lifted their FY2025 earnings per share (EPS) estimates for Abbott Laboratories in a report issued on Wednesday, October 15th. William Blair analyst B. Vazquez now forecasts that the healthcare product maker will post earnings of $5.16 per share for the year, up from their prior estimate of $5.14. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share. William Blair also issued estimates for Abbott Laboratories' Q4 2025 earnings at $1.51 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.37 EPS, Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.69 EPS, Q1 2027 earnings at $1.25 EPS, Q2 2027 earnings at $1.51 EPS, Q3 2027 earnings at $1.62 EPS and FY2027 earnings at $6.18 EPS.

A number of other research firms have also commented on ABT. Royal Bank Of Canada reiterated an "outperform" rating and set a $147.00 price objective on shares of Abbott Laboratories in a research note on Thursday. Benchmark began coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They set a "buy" rating and a $145.00 price objective on the stock. Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an "overweight" rating in a research note on Thursday. Sanford C. Bernstein raised their price objective on shares of Abbott Laboratories from $145.00 to $150.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a "buy" rating in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $147.44.

Abbott Laboratories Stock Performance

ABT opened at $127.38 on Friday. The business's 50 day moving average is $132.49 and its 200-day moving average is $131.56. The stock has a market cap of $221.70 billion, a PE ratio of 15.96, a price-to-earnings-growth ratio of 2.46 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting analysts' consensus estimates of $1.30. The company had revenue of $11.37 billion for the quarter, compared to analysts' expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.

Hedge Funds Weigh In On Abbott Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Carr Financial Group Corp lifted its position in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker's stock worth $520,000 after purchasing an additional 76 shares in the last quarter. Tortoise Investment Management LLC lifted its holdings in Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker's stock valued at $108,000 after buying an additional 77 shares during the period. Mayflower Financial Advisors LLC lifted its holdings in Abbott Laboratories by 0.5% in the first quarter. Mayflower Financial Advisors LLC now owns 17,327 shares of the healthcare product maker's stock valued at $2,298,000 after buying an additional 78 shares during the period. Gemmer Asset Management LLC lifted its holdings in Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker's stock valued at $368,000 after buying an additional 78 shares during the period. Finally, FF Advisors LLC lifted its holdings in Abbott Laboratories by 4.3% in the second quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker's stock valued at $259,000 after buying an additional 79 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.9%. Abbott Laboratories's payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.